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The objective of this study was to identify drugs that received dose adjustments (DA) and pharmaceutical 
alternatives (PA) that avoid DA, and calculate the economic percentage of this replacement. A descriptive, 
observational and cross-sectional study was performed in a second level hospital. The pharmacy and 
nursing services was accompanied to identify the drugs that received DA and the compounding techniques. 
After identifying all the drugs that received DA, was identified in the Brazilian market the corresponding 
pharmaceutical alternative, with the Drugs Price List of Brazilian Health Regulatory Agency. For those 
drugs that was not available any PA, was performed a research of studies that describe compounding 
techniques in international scientific databases. Was identify 88 drugs that received DA, and these, 50 
do not have any PA. Were identified compounding techniques to 40 drugs. Although any drug has your 
own particularity of compounding, the compounding techniques can be grouped in five categories. The 
standardization of 29 drugs can reduce in 28% the DA procedure and cost saving of 34,85%/month. 
We can conclude that every three drugs prescribed, one received DA and every three DA, one can be 
avoided by the selection of 29 PA, saving cost as well. The use and standardization of five techniques 
would attend the pharmaceutics recommendations for better dissolution, bioavailability and patient safety.
Uniterms: Pharmaceutical preparations/hospitals. Patient safety. Pharmacoeconomics. Drugs/descritive 
study/ Off-Label Use.
INTRODUCTION
Dose adjustment (DA) is performed to supply a 
patient’s therapeutic needs when non-standard dosages 
are needed (Brasil, 2007; FDA, 2013). The lack of liquid 
pharmaceutical forms for oral use on the market has 
become a problem for the pharmacotherapy of patients 
that primarily uses liquid formulations, such as pediatric 
patients, the elderly, patients receiving drugs via probe, 
patients with dysphagia, and patients with dementias, 
Parkinson’s, or Alzheimer’s disease (Haywood, Glass, 
2013; Thombre, Berchielli, Rogers, 2014). Patients with 
these problems require extemporaneous oral preparations 
in order to ensure the patient’s therapy. DA is common in 
health systems; however, there are no guarantees regarding 
the quality, effectiveness, and safety of drugs after DA 
and DA can expose the patient to adverse events (Glass, 
Haywood, 2006).
With the aim of ensuring the pharmacotherapy of 
the patient, contributing to the culture of patient safety, 
and objectively identifying drugs that underwent DA 
and pharmaceutical alternatives (PAs) that could avoid 
DA, we compared DA to the compounding techniques 
described in the literature and calculated the economy 
of PAs.
METHODS
Study design
This was a pharmaco-epidemiological, descriptive, 
and observational cross-sectional study based on the 
guideline Strengthening the Reporting of Observational 
studies in Epidemiology (STROBE) (Von Elm et al., 
2008).
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Study site 
This study was conducted at the State Hospital 
Américo Brasiliense (HEAB) in Américo Brasiliense, São 
Paulo state. The hospital assists patients from 24 cities in 
the region.
Study period 
Patient prescriptions were monitored in July 2013.
Data collect 
Patient prescriptions were monitored daily. The 
nursing staff’s work was monitored to check the drug 
manipulation techniques, administration, and storage 
after DA. The PAs and the costs were identified in the 
Brazilian market with the Drugs Price List of ANVISA 
(ANVISA, 2015). The DAs were classified into derivation 
or subdivision of the pharmaceutical form, according to 
the current legislation (Brasil, 2007). For those drugs 
without available PAs, studies that describe compounding 
techniques were studied, using the descriptors: “Drug 
name” – for each drug; “Drug Compounding”; “Drug 
Stability”; and “Pharmaceutical Preparations” in the 
databases LILACS, SciELO, and PubMed.
Ethical considerations
The study was approved by the ethics committee of 
the Institute Lauro de Souza Lima as the project “Proposta 
de implantação de um serviço de farmacovigilância no 
Hospital Estadual de Américo Brasiliense” under protocol 
E-015/10; it was also approved by the hospital board.
RESULTS
DA was identified in 88 (34.7%) different drugs 
of the 253 standardized drugs in the hospital pharmacy 
(Figure 1). The technique of derivation was standardized 
and described in the standard operating procedure as 
crushing the solid dosage form with the aid of a pestle, 
followed by immediate administration. The subdivision 
of the pharmaceutical form occurred in the hospital 
NOTE: DA: Dose Adjustment; PA: Pharmaceutical alternatives.
FIGURE 1 - Flowchart analysis of prescriptions of hospitalized patients, identification of dose adjustments, and pharmaceutical 
alternatives in the Brazilian market and the compounding techniques available in the literature.
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pharmacy and was performed by the pharmacy team. The 
subdivision technique used specialized equipment for this 
purpose, followed by packing and labeling with product 
information, including the active ingredient, expiry date, 
and batch number. Subdivisions of liquid dosage forms 
occurred in the ward in drug handling rooms by the 
nursing team. Only a portion of the ampoule contents were 
administered, corresponding to the desired concentration. 
No DA exceeded the shelf life of 48 hours.
In the Brazilian market, 29 PAs were identified for 
the 88 drugs that received DA, possibly decreasing DAs 
by 28.5% (856 / 2,998) (Table I). 
For the 50 drugs that lacked PAs, 40 had known 
compounding techniques (Table II); the following ten drugs 
(or drug combinations) had no published compounding 
techniques: bisacodyl; citalopram; a combined dose of 
rifampicin, isoniazid, pyrazinamide, and ethambutol; 
doxazosin; finasteride; isosorbide; ivermectin; paracetamol 
and codeine combined; quetiapine; and sertraline.
Regarding the microbiological quality, studies show 
the necessity of adding parabens, such as methylparaben 
and propylparaben, in the extemporaneous formulations 
and refrigerated storage to avoid microbiological growth 
(OPAS, 1997; Haywood, Glass, 2013; Alemón-Medina 
et al.,, 2014).
Furthermore, the hospital spent US$ 3,458.39 on 
performing DA. The economic analysis was calculated 
through the difference between the sum of DA (considering 
the frequency and cost for dosage form unity for each drug 
- for solid drugs, it was considered one tablet or capsule, 
and for liquid drugs, one milliliter) and the sum of the 
corresponding PA dosage (Table 1).
Through economic analysis, standardizing PAs 
could generate a cost savings of US$ 1,205.59. Only one 
drug (piperacilin + tazobactam powder for injection 4 g + 
0.5 g) is responsible for US$ 1,190.41 of this cost savings.
DISCUSSION
DA is an indispensable practice in hospitals because 
many patients often have specific needs that require 
the administration of drugs in various dosage forms 
(Haywood, Glass, 2013; Thombre, Berchielli, Rogers, 
2014).
Generally, these patients are those who make use 
of catheters, have dysphagia, and/or require different 
doses of commercialized drugs. Therefore, of every 
four hospitalized patients, three patients require at least 
one PA to one or more prescribed drugs; however, the 
standardization of 29 PAs may reduce DA practices by 
one-third.
Nevertheless, the Pan American Health Organization/
World Health Organization recommends preparing 
reduced therapeutic forms in order to facilitate the logistics 
(acquisition, storage, and distribution) of drugs, promoting 
the drug’s rational use, avoiding duplication and saving 
money by avoiding waste (OPAS, 1997).
On the other hand, ensuring the safety, efficacy, 
and quality of pharmaceutical forms is given by the 
pre-registration of drugs through stability studies (short 
and long), pharmaceutical equivalence studies, such as 
dissolution profiles and other pharmacopoeia analysis, and 
in vitro studies of bioequivalence aspects (Mastroianni, 
Lucchetta, 2011). These issues are no longer guaranteed 
after DA.
In addition, it is recommended that therapeutic forms 
be updated every two years, not just for the inclusion or 
exclusion of drugs, but also to review the submissions to 
ensure the best posology for the patient profile (OPAS, 
1997). Once the drugs were available to patients in the 
most appropriate pharmaceutical form and without 
manipulation (Catalán et al., 2001; Habib et al., 2014), 
patients would not be exposed to the inherent risks of DA 
(Paparella, 2010); this would also decrease costs.
Therefore, the data from this study highlight the 
importance of continuous expansion and revision of 
therapeutic forms, considering not only the managerial and 
administrative aspects of hospital pharmacy (selection, 
acquisition, and distribution of drugs), but also the 
management of patient safety at the institution.
For those drugs that do not have available 
commercial alternatives, DA is often inevitable. Every DA 
is considered off-label use, because it is a manipulation and 
formulation of extemporaneous doses from the marketed 
drugs (Kairuz et al., 2007; ANVISA, 2010; EMA, 2014; 
Carvalho, 2016); therefore, DA should be discussed by 
the health team and be provided in the clinical protocols 
of the service. 
Additionally, it was observed that derivation is 
standardized in the hospital and was based on the tablet 
dispersion technique, respecting the period of lateness (48 
hours) set by ANVISA (Brasil, 2007), showing conformity 
(Glass, Haywood, 2006). However, studies (Allen, 
2012; Alemón-Medina et al., 2014; Shoosanglertwijit 
et al., 2015) demonstrate that the validity of the PA is 
often greater than seven days, under certain criteria for 
manipulation and storage.
Glass and Haywood (Glass, Haywood, 2006) 
suggest a decision-flow for choosing the DA procedure. 
If there is need for an extemporaneous preparation of 
liquid, one must seek a commercially available alternative 
to avoid the DA. If none are available, the second option 
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would be to search for a therapeutic equivalent. If there 
is no therapeutic equivalent with the same efficacy and 
safety, the third option would be the preparation of an 
extemporaneous solution, according to the pharmacopoeia. 
When lacking the monograph of preparation, it is 
recommended to research a validated formulation. Without 
this, the literature should be used to find DA techniques 
specific to the drug. In a final decision, the standardized 
tablet dispersion technique should be used.
The advantage of technique standardization, as found 
in the literature review, is that it increases the stability of 
extemporaneous solutions and improves the dissolution 
TABLE I - Standard drugs that received dose adjustment and their classification and pharmaceutical alternatives available in the 
Brazilian market, which would avoid the need for dose adjustments
Standardized drugs DA Available commercially alternative
amiodarone (tablet 200 mg) SPF amiodarone (tablet 100 mg)
D amiodarone (oral solution 200 mg/mL)
amoxicillin + clavulanate (tablet 500 + 125 mg) D amoxicillin + clavulanate (powder for oral solution suspension 
50 mg/mL + 12.5/mL)
azithromycin (tablet 500 mg) D azithromycin (powder for oral solution suspension 40 mg/mL)
carbamazepine (tablet 200 mg) D carbamazepine (oral solution 20 mg/mL)
carvedilol (tablet de 25 mg) SPF carvedilol (tablet 12.5 mg)
clonazepam (tablet 0,5 mg) D clonazepam (oral solution 2.5 mg/mL)
clonazepam (tablet 2 mg) D clonazepam (oral solution 2.5 mg/mL)
complex B® [tablet - vitamin B1 (5mg); B2 
(1mg);B3(30mg); B5 (4mg); B6 (3mg)]
D Complex B® [oral solution - vitamin B1 (3 mg/mL); B2  
(3 mg/mL); B3 (10 mg/mL); B5 (25 mg/mL); B6 (10 mg/mL)]
dexamethasone (tablet 4 mg) D dexamethasone (elixir 0,1 mg/mL)
digoxin (tablet 0,25 mg) SPF digoxin (tablet 0.125 mg)
D digoxin (pediratric elixir 0,5 mg/mL)
domperidone (tablet 10 mg) D domperidone (oral solution 1mg/mL)
ferrous sulphate (tablet 250 mg) D ferrous sulphate (syrup 50 mg/mL)
fluoxetine (tablet 20 mg) D fluoxetine (oral solution 22,4 mg/mL)
folic acid (tablet 5 mg) D folic acid (oral solution 0.2 mg/mL)
haloperidol (tablet 5 mg) D haloperidol (oral solution 2 mg/mL)
lamivudine (tablet 150 mg) D lamivudine (oral solution 10 mg/mL)
levodopa + benserazide (tablet 200 mg + 50 mg) SPF levodopa + benserazide (tablet 100 mg + 25 mg)
lopinavir + ritonavir (tablet 200 + 50 mg) D lopinavir + ritonavirr (oral solution 80 + 20 mg/mL)
loratadine (tablet 10 mg) D loratadine (oral solution 1 mg/mL)
metronidazole (tablet 400 mg) D metronidazole (oral solution 40 mg/mL)
oseltamivir (capsule 75 mg) D oseltamivir (powder for oral suspension 12 mg/mL)
piracetam (tablet 400 mg) D piracetam (oral solution 60 mg/mL)
phenobarbital (tablet 100 mg) D phenobarbital (oral solution 40 mg/mL)
piperacillin + tazobactam (powder for injection 
solution 4 g + 0,5 g)
SPF piperacillin + tazobactam (powder for injection solution 2 g + 
0,25 g)
risperidone (coated tablet 1 mg) D risperidone (oral solution 1 mg/mL)
risperidone (coated tablet 2 mg) D risperidone (oral solution 1 mg/mL)
scopolamine (dragee 10 mg) D scopolamine (oral solution 10 mg/mL)
tramadol (capsule 50 mg) D tramadol (oral solution 100 mg/mL)
valproic acid (capsule 250 mg) D valproic acid (oral solution 50 mg/mL)
Note: DA: Dose Adjustment; D: Derivation; SPF: Subdivision of pharmaceutical form.
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of the drugs, thereby ensuring greater bioavailability 
and absorption, ensuring therapeutic effectiveness, and 
preventing adverse drug events. Moreover, changes in 
drug dosage forms can lead to changes in the polymorphic 
and morphological behaviors of drugs, which may cause 
therapeutic ineffectiveness, because while medicines are 
produced and stored, they tend to seek the most stable 
form, which is not always the more active and safe form 
(Glass, Haywood, 2006; Capucho, Mastroianni, Cuffini, 
2008; Paparella, 2010; Glass, Haywood, 2013).
The techniques found for the production of 
extemporaneous solutions are generally characterized by 
choosing the most appropriate vehicle (water or simple 
syrup) and the addition of pharmaceutical adjuvants, 
such as those used for suspending, thickening, binding, 
and acidifying. Other commercial alternatives, such as 
galenical bases, could be used to prepare extemporaneous 
solutions. This option for the preparation of DA, in order 
to ensure the quality of freshly-prepared solution and 
promote increased patient safety, will require periodic 
review.
A limitation of the study was the data collection 
time, a month, which can be a limitation for DA frequency 
analysis; however, the analysis period was not qualitatively 
limiting to identify the drugs that received DA, and 
other studies showed similar numbers of patients and 
prescriptions analyzed (Joosub et al., 2015; Mahmood 
et al., 2016). We believed that many of the 88 different 
drugs undergo DA in other hospitals, and the 40 techniques 
described in the literature may contribute to the stability, 
safety, and quality of such preparations.
Thus, data from this study suggest the need to 
change the selection process and standardization of drugs 
and the need for cost-effectiveness and cost-benefit studies 
to evaluate the effectiveness and safety of DA.
These data close a gap in the literature, contributing 
to our understanding of the inherent risks of DA and 
identifying potential cost savings.
TABLE II - Categories of manipulation techniques available in the literature regarding the medicinal dosing adequacy for 40 drugs
Compounding techniques Drugs
Crush SDF, dispersion with water and immediate 
administration. acetylsalicylic acid (Jamal, Dumke, 2012). 
Crush SDF, adding suspending agent and SQT with 
syrup.
amlodipine (Loyd, 2006); amitriptyline (Gupta, 2009); ciprofloxacin 
(Johnson et al., 1988); clopidogrel (Skillman, Caruthers, Johnson, 
2010); diazepam (Newton, Schulman, Becker, 1976; Strom, Agbai, 1986); 
lamotrigine (Nahata, Morosco, Hipple, 1999); levodopa and carbidopa 
(Nahata, Morosco, Leguire, 2000); pyrimethamine (Nahata, Morosco, 
Hipple, 1997); prednisone (Gupta, Gibbs, Ghanekar, 1978).
Crush SDF, adding suspending agent and other agents 
(humectants, binders and / or acidifying) and SQT with 
syrup.
atenolol (Patel, Doshi, Desai, 1997); baclofen (Johnson, Hart, 1993); 
gabapentin (Nahata, 1999); lorazepam (Wan-Man et al., 2004); losartan 
(Allen, 2012); metoprolol (Allen, Erickson, 1996); norfloxacin (Boonme 
et al., 2000); topiramate (Loyd, 2009).
Crush SDF, adding agents (humectants, binders, 
acidifiers and thickeners) and SQT with syrup.
captopril (Lye et al., 1997); diltiazem (Allen, Erickson, 1996); tenofovir 
(King et al., 2011).
Crush SDF, adding other agents (humectants, binders, 
acidifying, alkalizing and thickeners).
carvedilol (Yamreudeewong, Dolence, Deborah, 2006); clobazam 
(Buontempo et al., 2013); clonidine (Ma, Decarie, Ensom, 2014); 
donepezil (Yamreudeewong, Dolenc, Pahl, 2006); spironolactone 
(Salgado et al., 2005); enalapril (Nahata, Morosco, Hipple, 1998); 
phenytoin (Viriyaroj et al., 2009); fluconazole (Yamreudeewong, Lopez-
Anaya, Rappaport, 1993); furosemide (Shoosanglertwijit et al., 2011); 
hydralazine (Okeke et al., 2003); hydrochlorothiazide (Santoveña, 
Hernández-Paiz, Fariña, 2012); levothyroxine (Alexander, Kothapalli, 
Dollimor, 1997); metformin (Alemón-Medina et al., 2014); omeprazole 
(Kaufman et al., 2002); propranolol (Ensom et al., 2013); sulfadiazine 
(Pathmanathan et al., 2004); warfarin (Haywood, Glass, 2013);
They should not be administered by gavage (tube 
obstruction, lack of information or instability)
calcium carbonate (Jamal, Dumke, 2012); simvastatin (Jamal, Dumke, 
2012).
Note: SDF: solid dosage form; SQT: sufficient quantity to.
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For every three dispensed drugs, one received DA, 
and three of every four patients needed at least one of their 
drugs to undergo DA in their drug therapy, highlighting 
the importance and relevance of this practice in hospitals. 
Furthermore, for every three DA, one could be avoided 
with the selection of a PA. Each drug has its peculiarities 
for ensuring dissolution, bioavailability, and absorption 
of the drugs, consequently promoting safe and effective 
pharmacotherapy. 
Therefore, data from this study corroborate the need 
for cost-benefit studies to evaluate the effectiveness, safety, 
and economy generated by the DA process.
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